{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:03:08Z","timestamp":1773230588935,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.7759\/cureus.104989","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:22:32Z","timestamp":1773156152000},"source":"Crossref","is-referenced-by-count":0,"title":["Shift in Patterns of Care and Survival Outcomes of Hepatocellular Carcinoma in a Canadian Provincial Cancer Program"],"prefix":"10.7759","author":[{"given":"Nikunj","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie","family":"Nashed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miray","family":"Eskandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Shenouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Cassano-Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hepatocellular carcinoma in 2021: an exhaustive update","volume":"13","author":"Philips CA","year":"2021","unstructured":"Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular carcinoma in 2021: an exhaustive update. Cureus. 2021, 13:e19274.","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref3","unstructured":"Canadian Cancer Society. Cancer statistics. (2023). https.\/\/cancer.ca\/en\/research\/cancer-statistics."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio AA","year":"2020","unstructured":"Florio AA, Ferlay J, Znaor A, et al.. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020, 126:2666-78. 10.1002\/cncr.32803","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32723","article-title":"International trends in hepatocellular carcinoma incidence, 1978-2012","volume":"147","author":"Petrick JL","year":"2020","unstructured":"Petrick JL, Florio AA, Znaor A, et al.. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020, 147:317-30. 10.1002\/ijc.32723","journal-title":"Int J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70018","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians","volume":"75","author":"Moris D","year":"2025","unstructured":"Moris D, Martinino A, Schiltz S, et al.. Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians. CA Cancer J Clin. 2025, 75:498-527. 10.3322\/caac.70018","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei TH","year":"2025","unstructured":"Taddei TH, Brown DB, Yarchoan M, Mendiratta-Lala M, Llovet JM. Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2025, 82:272-4. 10.1097\/HEP.0000000000001269","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig M","year":"2026","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, et al.. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol. 2026, 84:631-54. 10.1016\/j.jhep.2025.10.020","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan DJ","year":"2022","unstructured":"Tan DJ, Ng CH, Lin SY, et al.. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022, 23:521-30. 10.1016\/S1470-2045(22)00078-X","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1923","article-title":"Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies","volume":"6","author":"Reveron-Thornton RF","year":"2022","unstructured":"Reveron-Thornton RF, Teng ML, Lee EY, et al.. Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies. Hepatol Commun. 2022, 6:1813-26. 10.1002\/hep4.1923","journal-title":"Hepatol Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35720","article-title":"Meta-analysis of randomized controlled trials of external-beam radiation versus transarterial chemoembolization for hepatocellular carcinoma","volume":"131","author":"Kuehnle RA","year":"2025","unstructured":"Kuehnle RA, Tchelebi LT, Ludmir EB, et al.. Meta-analysis of randomized controlled trials of external-beam radiation versus transarterial chemoembolization for hepatocellular carcinoma. Cancer. 2025, 131:e35720. 10.1002\/cncr.35720","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199303000-00002","article-title":"Registries and administrative data. Organization and accuracy","volume":"31","author":"Roos LL","year":"1993","unstructured":"Roos LL, Mustard CA, Nicol JP, McLerran DF, Malenka DJ, Young TK, Cohen MM. Registries and administrative data. Organization and accuracy. Med Care. 1993, 31:201-12. 10.1097\/00005650-199303000-00002","journal-title":"Med Care"},{"key":"ref13","article-title":"Section II: average annual registry-specific cancer incidence by race and sex","author":"Hotes Ellison J","year":"2006","unstructured":"Hotes Ellison J, Wu XC, McLaughlin C, et al.. Section II: average annual registry-specific cancer incidence by race and sex. Cancer in North America: 1999-2003, Volume I: Incidence. North American Association of Central Cancer Registries, Springfield (IL); 2006."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik L","year":"2019","unstructured":"Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019, 156:477-491.e1. 10.1053\/j.gastro.2018.08.065","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2220856","article-title":"Alcohol use and hepatocellular carcinoma risk in patients with alcohol-related cirrhosis","volume":"58","author":"Kraglund F","year":"2023","unstructured":"Kraglund F, Birn-Rydder R, S\u00f8rensen MD, Abazi R, Villadsen GE, Jepsen P. Alcohol use and hepatocellular carcinoma risk in patients with alcohol-related cirrhosis. Scand J Gastroenterol. 2023, 58:1321-7. 10.1080\/00365521.2023.2220856","journal-title":"Scand J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02521.x","article-title":"Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases","volume":"104","author":"Verrill C","year":"2009","unstructured":"Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases. Addiction. 2009, 104:768-74. 10.1111\/j.1360-0443.2009.02521.x","journal-title":"Addiction"},{"key":"ref17","unstructured":"Government of Canada. Report on Hepatitis B and C Surveillance in Canada. 2019. (2019). https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/report-hepatitis-b-c-canada-2019.html."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090313","article-title":"Evidence-based clinical guidelines for immigrants and refugees","volume":"183","author":"Pottie K","year":"2011","unstructured":"Pottie K, Greenaway C, Feightner J, et al.. Evidence-based clinical guidelines for immigrants and refugees. CMAJ. 2011, 183:E824-925. 10.1503\/cmaj.090313","journal-title":"CMAJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10903-005-5118-y","article-title":"Disparities in mortality patterns among Canadian immigrants and refugees, 1980-1998: results of a national cohort study","volume":"7","author":"DesMeules M","year":"2005","unstructured":"DesMeules M, Gold J, McDermott S, et al.. Disparities in mortality patterns among Canadian immigrants and refugees, 1980-1998: results of a national cohort study. J Immigr Health. 2005, 7:221-32. 10.1007\/s10903-005-5118-y","journal-title":"J Immigr Health"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.026","article-title":"Immigration and viral hepatitis","volume":"63","author":"Sharma S","year":"2015","unstructured":"Sharma S, Carballo M, Feld JJ, Janssen HL. Immigration and viral hepatitis. J Hepatol. 2015, 63:515-22. 10.1016\/j.jhep.2015.04.026","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01583.x","article-title":"Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma","volume":"19","author":"Chen W","year":"2012","unstructured":"Chen W, Tomlinson G, Krahn M, Heathcote J. Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma. J Viral Hepat. 2012, 19:574-80. 10.1111\/j.1365-2893.2012.01583.x","journal-title":"J Viral Hepat"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025, 82:315-74. 10.1016\/j.jhep.2024.08.028","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj.2019-0015","article-title":"Epidemiology, clinical treatment patterns, and survival of\u00a0hepatocellular carcinoma in Manitoba","volume":"3","author":"Hanumanthappa N","year":"2020","unstructured":"Hanumanthappa N, Cho BH, McKay A, Peretz D, Y Minuk G, Lambert P, Nashed M. Epidemiology, clinical treatment patterns, and survival of\u00a0hepatocellular carcinoma in Manitoba. Can Liver J. 2020, 3:194-202. 10.3138\/canlivj.2019-0015","journal-title":"Can Liver J"},{"key":"ref24","unstructured":"Survival statistics for liver cancer, Canadian Cancer Society [Internet]. Available from. https.\/\/cancer.ca\/en\/cancer-information\/cancer-types\/liver\/prognosis-and-survival\/survival-statistics."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel M","year":"2012","unstructured":"Burrel M, Reig M, Forner A, et al.. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012, 56:1330-5. 10.1016\/j.jhep.2012.01.008","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet JM","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, et al.. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002, 359:1734-9.","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458720-shift-in-patterns-of-care-and-survival-outcomes-of-hepatocellular-carcinoma-in-a-canadian-provincial-cancer-program","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:22:37Z","timestamp":1773156157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458720-shift-in-patterns-of-care-and-survival-outcomes-of-hepatocellular-carcinoma-in-a-canadian-provincial-cancer-program"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.104989","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}